Amyl Therapeutics

About:

Amyl Therapeutics is a preclinical stage biotechnology company.

Website: https://www.amyltx.com

Top Investors: Meusinvest (Noshaq), Mérieux Equity Partners, Sambrinvest, Smedvig, Evren Ucok

Description:

Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

Total Funding Amount:

29.7M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Liège, Liege, Belgium

Founded Date:

2020-11-01

Founders:

Florent Gros, Pierre Vandepapelière

Number of Employees:

1-10

Last Funding Date:

2023-11-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai